The checkpoint idea rests on a piece of chemistry that is easy to state and easier to underestimate. Cells almost never use ATP in its free form; the molecule is biologically active as a magnesium–ATP complex, in which Mg²⁺ coordinates the phosphate chain, reshapes its charge and geometry, and determines whether phosphoryl transfer — the fundamental transaction of cellular energy — can proceed at all. Magnesium is an essential cofactor for more than 600 enzymes, spanning every step of glycolysis and the tricarboxylic acid cycle as well as the catalytic core of ATP synthase itself. The consequence is a phenomenon the reviewers call functional ATP deficiency: when free Mg²⁺ becomes limiting, the pool of usable MgATP contracts even while total adenylate charge looks preserved, leaving the cell rich in fuel but poor in ignition. Because kinases employ MgATP rather than free ATP as their true substrate, everything from growth-factor signaling to nucleotide interconversion through adenylate kinase is tuned by magnesium availability. The ion does not merely sit upstream of metabolism, the authors argue — it is embedded within its currency.

Nowhere is the ratio of energy demand to safety margin steeper than in the kidney. Though it accounts for less than 1 percent of total body mass, the kidney consumes 20 to 25 percent of resting oxygen, filtering roughly 180 liters of plasma each day and reclaiming 99 percent of water and electrolytes through the active-transport machinery of proximal tubular cells, whose densely packed mitochondria power the Na⁺/K⁺-ATPase pumps. These cells are obligate aerobes operating on the precipice of hypoxia. After ischemic or toxic injury, surviving tubular cells suppress mitochondrial fatty acid oxidation and pivot toward aerobic glycolysis — a Warburg-like adaptation that preserves ATP under low oxygen but becomes maladaptive when sustained, starving the kidney of its high-efficiency energy source and driving ATP depletion, lipid accumulation, and a pro-fibrotic senescence-associated secretory phenotype. Current models of this failure fixate on the fuel: fatty acids, glucose, glutamine. The review contends that the field has overlooked the machinery, and that the transition from acute kidney injury to chronic kidney disease is best understood as a collapse of what the authors call the Mg–Ca–mitochondria axis.

That axis begins as a biophysical standoff between two cations. Under healthy conditions, cytosolic magnesium restrains the mitochondrial calcium uniporter, the inner-membrane channel that admits Ca²⁺ into the matrix, holding calcium signaling within a productive range. In states of injury — cisplatin nephrotoxicity and ischemia–reperfusion among them — intracellular magnesium is rapidly lost. The brake comes off the uniporter, calcium floods the matrix, the mitochondrial permeability transition pore opens, and the transmembrane potential that drives ATP synthesis collapses. A mitochondrion in this state is not merely idle: it converts from an energy generator into a source of reactive oxygen species and an arbiter of regulated cell death, including necroptosis and ferroptosis. Magnesium, in this framing, functions as a mitochondrial guardian whose availability draws the line between adaptive mitochondrial activation and catastrophic bioenergetic failure — a line that renal epithelial cells, with their punishing metabolic schedules, walk continuously.

The review then maps the infrastructure that sets magnesium availability in the first place. Systemic balance reflects intestinal absorption, renal excretion, and skeletal storage, but the decisive fine-tuning happens in the distal convoluted tubule, where magnesium enters epithelial cells through the TRPM6/TRPM7 complex — a chanzyme that fuses an ion channel pore with a kinase domain. Cryo-electron microscopy shows that the functional channel assembles as a heterotetramer of TRPM6 and TRPM7 subunits, driven by the electrochemical gradient across the apical membrane. The clinical stakes are vivid: loss-of-function mutations in TRPM6 cause hypomagnesemia with secondary hypocalcemia, a severe hereditary magnesium-wasting disease. Exit is equally engineered. Cytosolic Mg²⁺ must be extruded across the basolateral membrane against both chemical and electrical gradients by CNNM2 — whose mutations cause dominant familial hypomagnesemia — with PRL phosphatases binding its regulatory domain to suppress efflux and retain magnesium inside the cell. At the mitochondrial inner membrane, the pentameric channel MRS2, a eukaryotic relative of bacterial CorA recently resolved in both open and closed conformations, conducts Mg²⁺ into the matrix in a process governed by membrane potential, while the transporter SLC41A3 mediates efflux to prevent pathological accumulation.

Inside the matrix, magnesium touches every major station of energy conversion. It regulates rate-limiting tricarboxylic acid cycle enzymes, including isocitrate dehydrogenase and α-ketoglutarate dehydrogenase; it is required for the F₁F₀-ATP synthase, whose nucleotide binding and release occur within a magnesium-coordinated framework; and it is so integral to energy trafficking that the mitochondrial carrier SCaMC transports MgATP specifically, distinguishing the magnesium-bound nucleotide from free ADP and ATP. Magnesium even behaves as a signal in its own right. Recent work that repositioned lactate as a second messenger showed that L-lactate triggers the release of Mg²⁺ from endoplasmic reticulum stores and its subsequent uptake into mitochondria through MRS2, coupling glycolytic output directly to mitochondrial chemistry. Matrix magnesium, in other words, is not a passive buffer but a mobile message announcing the cell’s carbon-flux state. Experiments reinforce the point: limiting MRS2-dependent uptake induces metabolic reprogramming under prolonged dietary stress, while inducible loss of MRS2 in animals produces profound mitochondrial dysfunction — evidence that mitochondrial magnesium influx is instructive for metabolism rather than redundant.

From this biochemistry the review extends directly into metabolic disease. Hypomagnesemia affects roughly one third of people with type 2 diabetes, and the mechanistic case runs through MgATP-dependent signaling. When cytosolic free Mg²⁺ falls, the insulin receptor’s tyrosine kinase and the downstream phosphorylation cascade — IRS, PI3K, and AKT — lose phosphoryl-transfer efficiency, degrading robust, switch-like signal propagation into a leaky, delayed network in which insulin binding no longer reliably delivers the GLUT4 glucose transporter to the membrane. Simultaneously, low intracellular magnesium amplifies oxidative stress and stress kinases such as JNK and p38, which tag IRS proteins with inhibitory serine phosphorylations, entrenching a resistance that insulin dose escalation cannot rescue. The result is the familiar clinical picture: high circulating insulin alongside persistent hepatic glucose output, defective skeletal-muscle glucose disposal, and insufficiently suppressed lipolysis. The authors also describe a self-reinforcing renal–metabolic loop. Glycosuria-driven osmotic diuresis increases urinary magnesium losses, diabetic nephropathy erodes reabsorptive reserve, and common drugs such as diuretics and proton pump inhibitors push balance further toward depletion. Because insulin itself modulates epithelial magnesium transport, insulin resistance decouples hormonal cues from the kidney’s reabsorption capacity, converting the kidney into a metabolic amplifier of the deficiency.

What about simply taking more magnesium? The trial evidence is encouraging but conditional. Meta-analyses of randomized studies generally support modest improvements in fasting glucose, insulin, and HOMA-IR, with the largest effects among people who begin with hypomagnesemia or impaired glucose regulation; in established diabetes dominated by advanced ectopic lipid burden, inflammation, or comorbid kidney disease, supplementation does not uniformly restore insulin sensitivity. The reviewers therefore propose a tiered, mechanism-informed strategy in place of one-size dosing. The first tier identifies magnesium depletion, recognizing that serum magnesium — the standard clinical test — is a poor proxy for intracellular and mitochondrial pools and should be read alongside renal risk factors and medication exposures. The second tests whether repletion actually restores signaling responsiveness, using dynamic measures such as postprandial glycemia or clamp-derived indices. The third corrects the drivers that perpetuate depletion, from tubular magnesium wasting to impaired intestinal absorption and offending medications — combination approaches that go well beyond a generic oral dose.

The review’s most provocative claim concerns time. Cytosolic magnesium, it turns out, oscillates with circadian rhythm, and by tuning the cell’s global phosphorylation potential these oscillations can gate core timekeeping and energy-balance processes — prompting the authors to describe magnesium as a temporal metabolite that periodically rewrites what ATP can do. From this emerges the magnesium clock hypothesis: age-associated drift in mitochondrial magnesium acts as a hidden temporal regulator that narrows the margin between energetic demand and organelle tolerance until cells tip into senescence. Supporting pieces are accumulating. Magnesium restriction accelerates senescence in cultured human fibroblasts; silencing TRPM7, a major magnesium-entry chanzyme, is sufficient to induce replicative senescence; and matrix magnesium acts as a cationic rheostat restraining mitochondrial calcium uptake. When magnesium is lost, two safety margins compress at once — ATP-linked repair capacity falls while calcium-linked damage signaling rises — accelerating the engagement of p53 and p16 pathways that lock cells into growth arrest. Senescent cells then secrete inflammatory mediators, inflammaging promotes further renal magnesium wasting, and the loop closes: magnesium depletion, mitochondrial fragility, and inflammatory signaling amplifying one another as tissue function declines.

The authors are notably explicit about the limits of their own synthesis. Mechanistic plausibility, they caution, is not demonstrated lifespan causality: while magnesium deficiency robustly accelerates senescence in vitro, no longitudinal study has yet tracked mitochondrial magnesium dynamics across the natural aging of a whole organism, and blood measurements cannot resolve what happens inside mitochondria. Their research agenda is correspondingly concrete: develop compartment-specific readouts of magnesium status, run longitudinal in vivo studies across the lifespan, and test whether genetic or pharmacological preservation of MRS2-dependent matrix magnesium can delay frailty or reduce cumulative senescence burden. Therapeutically, the direction of travel is away from blunt supplementation and toward transport-informed, compartment-specific modulation — restoring magnesium homeostasis at the level of specific channels, carriers, and organelles where bioenergetic control actually resides. On that view, magnesium is not a miracle mineral but something more interesting: a rational, testable, and potentially modifiable checkpoint where mitochondria, metabolism, and aging converge.

At its core, NAD⁺ serves as a quintessential electron carrier, shuttling electrons during metabolic reactions to sustain ATP production. However, its functions transcend mere redox chemistry. NAD⁺ is also a substrate for a collection of NAD⁺-dependent enzymes, including sirtuins, poly(ADP-ribose) polymerases (PARPs), and cyclic ADP-ribose synthases, which participate in regulating gene expression, DNA repair, and calcium signaling. These multifaceted roles position NAD⁺ as a lynchpin in maintaining cellular homeostasis, responding dynamically to physiological cues and stress.

Integral to the regulation of intracellular NAD⁺ levels is the nicotinamide phosphoribosyltransferase (NAMPT)-mediated salvage pathway. NAMPT catalyzes the conversion of nicotinamide (NAM), a byproduct of NAD⁺ consumption, back into nicotinamide mononucleotide (NMN), a direct NAD⁺ precursor. This salvage pathway not only ensures the replenishment of NAD⁺ pools but also intricately controls its availability to meet fluctuating cellular demands. Disruptions in NAMPT activity have been strongly correlated with pathological conditions, emphasizing the enzyme’s significance in human health and disease.

A decline in NAD⁺ levels is a well-documented hallmark of aging and a variety of stress-related states. This reduction compromises mitochondrial function, leads to the accumulation of DNA damage, and impairs metabolic flexibility, cumulatively destabilizing cellular homeostasis. These findings have instigated fervent exploration into therapeutic approaches centered on restoring or augmenting NAD⁺ concentrations as a means to combat age-associated decline and pathological disorders.

Supplementation with NAD⁺ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) has garnered significant attention, fueled by preclinical studies demonstrating improved mitochondrial function, enhanced DNA repair capacity, and mitigation of metabolic dysfunction. Clinical trials, though still nascent, have begun to corroborate these benefits, positioning NAD⁺ precursor administration as a promising avenue for therapeutic intervention in degenerative diseases and metabolic syndromes.

Among the most innovative strategies to modulate NAD⁺ metabolism is the pharmacological targeting of NAMPT. Activation of NAMPT represents a compelling method to elevate intracellular NAD⁺ levels more efficiently than precursor supplementation alone. One such activator, P7C3, originally recognized for its neuroprotective properties, has been shown to enhance NAMPT activity, thereby increasing NAD⁺ levels in human cells subjected to chemotherapeutic stress with doxorubicin. This evidence opens the door for P7C3 and similar compounds to be leveraged in treating age-related neurodegenerative conditions.

Moreover, enhancing NAMPT activity in mesenchymal stem cells (MSCs) through P7C3 treatment has been demonstrated to improve their therapeutic efficacy in alleviating inflammatory disorders. This highlights a broader potential utility of NAMPT activators—not solely in metabolic enhancement but also as adjuvants in regenerative medicine and immunomodulation. Such insights underscore NAD⁺ metabolism’s intersection with inflammation and immune responses, an area ripe for future investigation.

The discovery of SBI-797812, a highly potent small molecule NAMPT activator effective at nanomolar concentrations, further exemplifies the therapeutic promise of targeting the NAD⁺ salvage pathway. SBI-797812 not only boosts NMN production in vitro but also elevates NAD⁺ levels in vivo, indicating translational potential for clinical applications aimed at metabolic health and longevity.

Conversely, NAMPT inhibitors wield therapeutic potential in oncology. Cancer cells often exhibit rewired NAD⁺ metabolism to support their rapid proliferation and survival. Inhibitors such as KPT-9274 have been shown to disrupt lipid metabolism in acute myeloid leukemia cells, specifically reducing stearoyl-CoA desaturase activity, thereby inducing apoptosis. This dual role of NAMPT in both normal physiology and pathology encapsulates the nuanced balance required in targeting this enzyme.

Another promising anti-cancer strategy involves the NAMPT inhibitor FK866, which, when combined with platinum-based chemotherapy, suppresses the emergence of therapy-induced senescence-associated, cancer stem-like cells. This synergy points to the potential of combining metabolic pathway inhibitors with conventional chemotherapeutics to overcome resistance and improve patient outcomes.

Despite these advances, significant questions remain regarding the spatial and temporal regulation of NAD⁺ metabolism. NAD⁺ pools are compartmentalized distinctly within the cytoplasm, mitochondria, and nucleus, each mediating unique biochemical and signaling pathways. Understanding tissue- and organ-specific NAD⁺ dynamics is imperative to develop targeted therapies that maximize efficacy while minimizing off-target effects.

Furthermore, the long-term safety profile of chronic NAD⁺ supplementation requires rigorous assessment. While short-term interventions have demonstrated benefits, the potential for adverse effects or metabolic imbalances over prolonged use remains an open question. These considerations are critical as the field moves toward widespread clinical application.

Intriguing recent studies have also illuminated the role of NAD⁺ metabolism in modulating immune responses and inflammation. Given the centrality of immune dysregulation in numerous diseases—including autoimmune disorders and cancer—this avenue represents a highly promising frontier. Future research focused on the crosstalk between NAD⁺ metabolism and immune pathways could unlock novel therapeutic strategies.

Altogether, the burgeoning field of NAD⁺ metabolism research places NAMPT at its epicenter, highlighting its dualistic capacity to influence energy metabolism and epigenetic regulation. This enzyme’s centrality marks it as a prime target for interventions designed to restore cellular vitality in the face of aging, metabolic challenge, and malignancy.

Looking ahead, the challenge lies in harnessing the complexity of NAD⁺ biology to design precision therapies. This endeavor demands a multidisciplinary approach integrating molecular biology, pharmacology, and clinical science. Advances in high-resolution metabolomics and compartment-specific NAD⁺ measurement techniques will be pivotal to unravel this complexity.

Ultimately, leveraging NAD⁺ metabolism therapeutically holds the promise of reshaping treatment paradigms across a spectrum of diseases. As research continues to decode the intimate relationship between NAD⁺, cellular aging, and metabolic health, the prospect of extending healthspan and combating chronic disease through NAD⁺ modulation becomes increasingly tangible.

This synthesis of biochemical insight and therapeutic innovation heralds a new chapter in medicine—one where the fundamental currency of cellular energy, NAD⁺, becomes a fulcrum for enhancing human health and longevity.

Subject of Research:
Nicotinamide phosphoribosyltransferase (NAMPT) and NAD⁺ metabolism in physiology and pathology.

Article Title:
Nicotinamide phosphoribosyltransferase in NAD⁺ metabolism: physiological and pathophysiological implications.

Article References:
Zhang, W., Ren, H., Chen, W. et al. Nicotinamide phosphoribosyltransferase in NAD⁺ metabolism: physiological and pathophysiological implications. Cell Death Discov. 11, 371 (2025). https://doi.org/10.1038/s41420-025-02672-w

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41420-025-02672-w

The study highlights a novel sample introduction system that incorporates a microdroplet generator (µDG). Traditional methods in single-cell ICP-MS typically utilize a pneumatic nebulizer to aerosolize liquid samples. However, this approach has been hampered by a low transport efficiency, particularly for fragile mammalian cells. While some success has been achieved with yeast cells, the delicate structure of mammalian cells often leads to significant damage during the nebulization process. Consequently, the introduction of µDG could represent a transformative change in how we conduct elemental analysis at the cellular level.

Mammalian cells have a unique vulnerability due to their complex structures, which makes them susceptible to shear stress and resultant damage during the nebulization process. In conventional systems, the transport efficiency remains below 10%, which can severely compromise the integrity of the cells being analyzed. Furthermore, traditional chemical fixation methods, which are aimed at stabilizing cells, inadvertently alter their elemental composition. This distortion introduces inaccuracies that could affect the conclusions drawn from analyses. Therefore, the imperative for a reliable and non-destructive method for mammalian single-cell analysis is more pronounced than ever.

As detailed in the newcomers’ innovative study, the introduction of the µDG dramatically improves cell transport efficiency without sacrificing cell viability. By employing a specially designed T-shaped glass plumbing system, the researchers connected the µDG to both a total consumption spray chamber and an ICP torch. This configuration enabled them to introduce single-cell-containing droplets into the ICP-MS apparatus in a more efficient and stable manner. Their results were not only promising but also indicative of the potential for expanded applicability across various biological samples.

Throughout the study, researchers tested this advanced setup on human chronic myelogenous leukemia K562 cells, aiming to analyze crucial trace elements such as magnesium, iron, phosphorus, sulfur, and zinc. The findings revealed that the µDG preserved cellular structure, thereby leading to a more accurate representation of elemental contents when compared to conventional methods. This stability is critical for any subsequent analysis, as maintaining cell integrity ensures that the detected elemental signals are authentic and reliable.

By establishing that the µDG could facilitate effective detection of elemental signals from individual cells without compromising their structure, the team provided a fresh perspective on scICP-MS technology, advocating for its advantages in cell analysis. The experimental results demonstrated that harnessing the power of the µDG mitigates the previously acknowledged issues faced by traditional nebulization methods, thereby reinforcing the µDG’s role as a versatile and indispensable tool in the world of analytical chemistry.

Dr. Tanaka emphasized the potential impact of their findings on the future of clinical diagnostics. In his commentary, he elucidated that the application of scICP-MS could pave the way for more personalized medicine approaches, whereby elemental compositions within individual cells provide insights into health conditions. Particularly, blood cell samples can serve as crucial markers for disease prognosis and diagnosis, indicating shifts in cellular health that could be tied back to environmental exposure or systemic changes.

Moreover, the research showcased the procedural efficacy of utilizing the µDG in single-cell analyses, paving the way for further innovations within the discipline. The implications of this work extend far beyond the confines of a laboratory, signaling potential advancements across various fields, including environmental monitoring, pharmacology, and agricultural sciences. The study’s success illustrates the interplay between technological innovation and the pressing need for accurate and reliable batch size reductions in sample analysis.

In conclusion, the research conducted by Yu-ki Tanaka and his team represents a formidable step forward in the analytical capabilities afforded by ICP-MS technologies. The µDG’s introduction into single-cell analysis not only stands to enhance our understanding of elemental distributions within mammalian cells but also signifies a broader shift toward a more nuanced investigation of how trace metals influence biological systems. As the scientific community continues to grapple with contamination and exposure to heavy metals, this research offers a beacon of hope for improved analytical techniques that could ultimately inform public health initiatives and regulatory policies.

The team’s findings were officially reported in the Journal of Analytical Atomic Spectrometry, further solidifying their contributions to the scientific understanding of single-cell elemental analysis. With an increasing emphasis on precision and accuracy in biomedical research, studies such as this will pave the way for the next generation of diagnostics tools that could profoundly impact individual health management and disease prevention strategies.

Subject of Research: Cells
Article Title: Quantitative elemental analysis of human leukemia K562 single cells by inductively coupled plasma mass spectrometry in combination with a microdroplet generator
News Publication Date: December 2, 2024
Web References: Journal of Analytical Atomic Spectrometry
References: DOI: 10.1039/d4ja00364k
Image Credits: Credit: Dr. Yu-Ki Tanaka from Chiba University

Keywords

ICP-MS, microdroplet generator, single-cell analysis, trace metals, K562 cells, elemental analysis, biomedical research, diagnostics, Chiba University